In-vivo data support progression of solid tumour programmes

Laverock Therapeutics, a biotechnology company developing disease-responsive advanced therapies through programmable gene control technology, has generated new in-vivo data across its oncology pipeline, supporting further development of its lead T-cell and macrophage programmes in solid tumours.

The findings provide functional validation of the company’s platform, which enables programmable and multiplex gene regulation across endogenous targets and engineered therapeutic payloads. Together, the results support progression towards lead programme selection and eventual clinical translation.

In its T-cell programme (LVK201), Laverock is applying its technology to enhance CAR-T cell activity while maintaining control over safety. Data from ovarian cancer models, presented at the American Society of Cell and Gene Therapy (ASCGT) Annual Meeting in May, demonstrate improved tumour control through simultaneous modulation of three immunoregulatory pathways.

Earlier studies suggest the platform harnesses intrinsic T-cell activation dynamics, enabling therapeutic activity only under appropriate biological conditions — a mechanism that may help improve safety compared with conventional CAR-T approaches.

These combined datasets reinforce LVK201 as a strong candidate for further development and broaden the potential application of the platform across multiple solid tumour indications. The company will continue to build on these findings using AI-driven analysis and single-cell approaches supported by recent grant funding.

In parallel, the LVK301 macrophage programme is exploring how engineered myeloid cells can be used to reshape tumour biology. The platform enables control of macrophage phenotype and regulated delivery of immunomodulatory payloads.

In preclinical models, these engineered cells have demonstrated both direct tumour growth suppression and conversion of the tumour microenvironment from an immune-resistant ‘cold’ state to an inflamed ‘hot’ state, supporting immune activation against cancer.

Together, these results strengthen the case for macrophage-based approaches in oncology and highlight the broader potential of myeloid cell engineering beyond cancer applications.

Laverock is also working with external partners to refine its non-clinical and clinical development strategy, with the aim of accelerating a de-risked path to early clinical validation.

David Venables, CEO of Laverock Therapeutics, said: “These data highlight the strength of our platform and provide a clear path to lead programme selection and non-clinical progression. Solid tumours remain a major unmet need, and we look forward to advancing our therapies towards the clinic.”

More information online